Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized, double-blind, placebo-controlled study of PF-00489791 in pulmonary arterial hypertension
2008-003572-21Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PF-00489791 in Plexogenic Pulmonary Arteriopathy and pulmonary arterial hypertension (PAH) (4 arms), sponsored by Pfizer. Primary endpoint: Change in pulmonary vascular resistance index (PVRI). Started Aug 2008; status: terminated.
02
Drugs
PF-00489791
03
Conditions
Plexogenic Pulmonary Arteriopathypulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2008-003572-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003572-21.